Epidemiology of bronchiectasis.
Mattia Nigro, Irena F Laska, Letizia Traversi...
https://pubmed.ncbi.nlm.nih.gov/39384303/Actively Recruiting
Led by AstraZeneca · Updated on 2026-10-02
435
Participants Needed
186
Research Sites
26 weeks
Total Duration
Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients aged 12 years and older with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase IIb study compares two intravenous dosage regimens of AZD0292 to placebo, including participants with non-cystic fibrosis bronchiectasis NCFBE and an exploratory group with cystic fibrosis CF bronchiectasis. Participants will receive either a high dose or low dose of AZD0292 or placebo via IV infusion starting on Day 1, with further doses given according to the study schedule. The study uses a randomized, double-blind, placebo-controlled, parallel design to assess the drugs efficacy, safety, and pharmacokinetics. The primary focus is on PsA-colonized bronchiectasis patients who have frequent pulmonary exacerbations, with treatment continuing for a variable follow-up period. During the study, participants will be monitored regularly for exacerbation rates, lung function, quality of life measures, and adverse events. Assessments include sputum cultures, pulmonary function tests, serum pharmacokinetic sampling, and questionnaires like the QOL-B-RSS and SGRQ. Safety monitoring extends up to 24 weeks after the last dose, and the study duration varies from at least 28 weeks to a maximum of 52 weeks of follow-up.
CONDITIONS
A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization
A
AstraZeneca Clinical Study Information Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
AstraZeneca
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | High‑dose AZD0292 IV infusion | Low‑dose AZD0292 IV infusion | Placebo IV infusion | Long‑term inhaled antibiotic therapy |
|---|---|---|---|---|
| What it is | An investigational monoclonal antibody AZD0292 at a higher IV dose | The same investigational antibody at a lower IV dose | Placebo infusion given under the same schedule as investigational arms | Long‑term inhaled antibiotic therapy is used in current practice to reduce exacerbations in bronchiectasis with chronic Pseudomonas aeruginosa |
| Role in trial | One of two investigational treatment dosing arms | Alternative investigational dosing arm | Control arm using placebo infusion | Not part of the trial; represents usual care comparator in practice |
| Primary use | To prevent exacerbations by targeting chronic PsA colonization | Same preventive intent at lower dose | Acts as control to compare efficacy of AZD0292 dosing | To manage frequent exacerbations by reducing bacterial load over time |
| How it is given or performed | IV infusion starting on Day 1 per schedule of assessments | Same IV infusion schedule at a lower dose | IV infusion matching investigational schedules | Inhaled antibiotics administered daily or as long‑term maintenance per guideline |
| Evidence status | Efficacy under investigation; results pending | Efficacy under investigation; results pending | Serves as comparison; no therapeutic benefit expected | Long‑term inhaled antibiotics reduce exacerbation frequency in frequent exacerbators |
| Important limitations | No published data yet; trial results not available | No published data yet; unproven at lower dosing | Placebo does not reflect any active treatment | Eradication of Pseudomonas with inhaled antibiotics achieved in only ~40‑50% of cases and evidence remains conditional |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - At least 28 weeks up to 52 weeks
Participants receive either high-dose or low-dose AZD0292 or placebo via IV infusion according to the study schedule.
Multiple visits for dosing and assessments
Duration - Up to 24 weeks after final dose
Participants are monitored for safety, adverse events, and treatment effects up to 24 weeks after the last dose.
Regular safety follow-up visits
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Mattia Nigro, Irena F Laska, Letizia Traversi...
https://pubmed.ncbi.nlm.nih.gov/39384303/Jinhwa Song, Sooim Sin, Hye-Rin Kang...
https://pubmed.ncbi.nlm.nih.gov/39274224/Kiran Chawla, Shashidhar Vishwanath, Mohan K Manu...
https://pubmed.ncbi.nlm.nih.gov/25722615/Hayoung Choi, Jin-Fu Xu, Sanjay H Chotirmall...
https://pubmed.ncbi.nlm.nih.gov/39322263/David Araújo, Michal Shteinberg, Stefano Aliberti...
https://pubmed.ncbi.nlm.nih.gov/29386336/Merete B Long, Amy Gilmour, Margaret Kehl...
https://pubmed.ncbi.nlm.nih.gov/38754132/James D Chalmers, Pieter Goeminne, Stefano Aliberti...
https://pubmed.ncbi.nlm.nih.gov/24328736/Jonathan Guo, Anna Garratt, Andrew Hill
https://pubmed.ncbi.nlm.nih.gov/35125294/Matthew L Oswalt, Stephen F Kemp
https://pubmed.ncbi.nlm.nih.gov/17493497/D E Tabor, V Oganesyan, A E Keller...
https://pubmed.ncbi.nlm.nih.gov/30016475/AstraZeneca
Lead Sponsor